328446
Gender sensitive predictors of retention in opioid substitution treatment among long-term opioid users
Methods: Gender Matters was a cross-sectional study of long-term opioid users in the poorest neighbourhood of Vancouver. Participants self-reporting ≥ 28 days of OST in the prior month were considered retained, as per cut points designated in prior studies. Descriptive variables were recorded separately for men (n=94) and women (n=81), and a predictive model of retention was built for each gender using logistic regression.
Results: An identical proportion (54%) of participants were retained among both genders. Multivariable analysis revealed factors significantly associated with retention for men to include less days of illicit activities (AOR: 0.94; 95%CI: 0.90-0.98) and a lower likelihood of living with someone using illicit drugs (AOR: 0.23; 95%CI: 0.07-0.83). For women factors included, higher treatment satisfaction (AOR: 1.26; 95%CI: 1.10-1.46), higher dose (AOR: 6.14; 95%CI: 1.60-23.52), and being a mother (AOR: 5.41; 95%CI: 1.12-26.14).
Conclusions: Despite the same proportion of men and women being retained, predictors of retention differed by gender. Exploring and understanding gender-specific predictors can inform treatment that is tailored to specific patient needs, ultimately improving retention.
Learning Areas:
Public health or related researchLearning Objectives:
Identify gender sensitive predictors of retention in opioid substitution treatment among long-term opioid dependent men and women.
Keyword(s): Drug Abuse Treatment, Underserved Populations
Qualified on the content I am responsible for because: I am a PhD student at the University of British Columbiaâs School of Population and Public Health. My research focuses on Gender Matters (GeMa), a Canadian Institutes of Health Research funded study investigating gender sensitive patterns of drug use, treatment access, and victimization among long-term opioid dependent men and women.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.